Tarsus Pharmaceuticals, Inc. 8-K

What Happened

• Tarsus Pharmaceuticals, Inc. (TARS) announced on February 18, 2026 that its Board expanded from seven to eight directors and appointed David E.I. Pyott as a Class III director, effective immediately. Mr. Pyott’s term expires at the Company’s 2026 annual meeting of stockholders or until his successor is elected. The Board also named him Chairperson of the Commercial Committee and a member of the Nominating and Compensation Committees. The Board determined Mr. Pyott is independent under Nasdaq and SEC rules.

Key Details

• Board size increased from seven to eight directors; appointment effective February 18, 2026.
• Mr. Pyott will serve as a Class III director with a term through the 2026 annual meeting.
• Initial non-employee director compensation includes an equity grant with a target value of $540,000: 50% as stock options and 50% as restricted stock units (RSUs).
• The Company entered into its standard indemnification agreement with Mr. Pyott; no related-party transactions or special arrangements were reported.

Why It Matters

• A new, independent director and Commercial Committee chair can affect oversight of Tarsus’s commercialization strategy and governance.
• The $540,000 equity grant is standard non-employee compensation but will add share-based awards tied to future dilution and executive alignment.
• For investors, this is a governance and leadership update (not a financial result); monitor future filings or press releases for strategic or operational changes tied to this appointment.